Canopy Growth (CGC) Operating Income (2019 - 2025)
Canopy Growth (CGC) reported Operating Income of -$47.2 million for Q4 2025, down 176.98% on a YoY basis from $61.4 million in Q4 2024, and down 284.77% sequentially from -$12.3 million in Q3 2025.
Canopy Growth (CGC) Operating Income (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Operating Income data on file, last reported at -$47.2 million in Q4 2025.
- For the quarter ending Q4 2025, Operating Income fell 176.98% year-over-year to -$47.2 million; the trailing twelve-month figure through Dec 2025 stood at -$92.9 million (up 38.58% YoY), and the FY2026 full-year result was -$117.9 million, down 44.4% from the prior year.
- Operating Income eased to -$47.2 million in Q4 2025, from -$12.3 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$5.2 million in Q3 2023 to a low of -$1.4 billion in Q2 2022.
- A 5-year average of -$176.7 million and a median of -$79.2 million in 2024 frame the typical range for Operating Income.
- Across the five-year window, Operating Income plunged 846.31% in 2022 and jumped 97.18% in 2023, its largest moves.
- Tracing CGC's Operating Income over 5 years: stood at -$119.0 million in 2021, then jumped by 30.22% to -$83.0 million in 2022, then surged by 46.63% to -$44.3 million in 2023, then soared by 61.51% to -$17.1 million in 2024, then tumbled by 176.98% to -$47.2 million in 2025.
- Business Quant data shows CGC's Operating Income at -$47.2 million in Q4 2025, -$12.3 million in Q3 2025, and -$16.3 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -47.23 Mn |
| Sep 30, 2025 | -12.28 Mn |
| Jun 30, 2025 | -16.33 Mn |
| Dec 31, 2024 | -17.05 Mn |
| Sep 30, 2024 | -33.68 Mn |
| Jun 30, 2024 | -21.28 Mn |
| Mar 31, 2024 | -79.21 Mn |
| Dec 31, 2023 | -44.30 Mn |
| Sep 30, 2023 | -5.23 Mn |
| Jun 30, 2023 | -40.69 Mn |
| Mar 31, 2023 | -402.97 Mn |
| Dec 31, 2022 | -83.02 Mn |
| Sep 30, 2022 | -114.38 Mn |
| Jun 30, 2022 | -1.45 Bn |
| Mar 31, 2022 | -367.71 Mn |
| Dec 31, 2021 | -118.97 Mn |
| Sep 30, 2021 | -171.08 Mn |
| Jun 30, 2021 | -152.71 Mn |
| Mar 31, 2021 | -184.25 Mn |
| Dec 31, 2020 | -424.65 Mn |